Description_x000D_ General description_x000D_ Cytochrome P450 family 17 subfamily A member 1 (CYP17A1) is a member of the cytochrome P450 superfamily of enzymes. It is encoded by the gene mapped to human chromosome 10q24.32. This protein localizes to the endoplasmic reticulum._x000D_ Immunogen_x000D_ CYP17A1 (NP_000093, 363-398)_x000D_ This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the Center region of human CYP17A1._x000D_ Application_x000D_ Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below._x000D_ Western Blotting (1 paper)_x000D_ Physical form_x000D_ Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ Cytochrome P450 family 17 subfamily A member 1 (CYP17A1) catalyzes 17Α-hydroxylation of steroid substrates and cleavage and oxidation of their side-chains. It has both 17Α-hydroxylase and 17, 20-lyase activities. The protein acts as a key enzyme in the synthesis of cortisol, testosterone and oestrogen. Mutations in CYP17A1 gene are associated with mineralocorticoid excess syndromes, glucocorticoid and sex hormone deficiencies. In addition, it also increases the risk of susceptibility to prostate cancer, benign prostatic hypertrophy and occasional congenital adrenal hyperplasia (CAH). Abiraterone inhibits steroidogenic activity of CYP17A1 and retards tumor growth in castration-resistant prostate cancer (CRPC) patients.